Last checked at 1 Apr 2022 07:00
Belluscura plc
("Belluscura" or the "Company" or "Group")
Notice of AGM and Annual Report 2021
LONDON, U.K. AND PLANO, TX, U.S. (1 April 2022). Belluscura plc (AIM:BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that the Notice of Annual General Meeting ("Notice") is being posted shareholders today and will shortly be available on the Company's website at: https://investors.belluscura.com/investors/shareholder-information.
The Annual Report and Accounts for the year ended 31 December 2021 is being posted along with the Notice and will be available on the Company's website at: https://investors.belluscura.com/investors/annual-interim-reports.
If you wish to submit a proxy vote for this meeting, please submit your vote online at www.signalshares.com. For your vote to be valid please ensure that it is received by no later than 12.00 NOON on 21 April 2022. Alternatively, should you wish to vote via the CREST system, please see the instructions in the Notice.
For further information please contact:
Belluscura plc | www.belluscura.com |
Robert Rauker, Chief Executive Officer | via Walbrook PR |
Anthony Dyer, Chief Financial Officer | |
SPARK Advisory Partners Limited (NOMAD) | Tel: +44 (0)20 3368 3550 |
Neil Baldwin | |
Dowgate Capital Limited (Broker) | Tel: +44 (0)20 3903 7715 |
James Serjeant / Nicholas Chambers | |
Walbrook PR Ltd (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or belluscura@walbrookpr.com |
Paul McManus / Sam Allen | Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 |
About Belluscura plc (www.belluscura.com)
Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.